Autopsy report · NCT03829657

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

“Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 9 months before it stopped.
• 203 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Theravance Biopharma

Sponsor type

Industry

Conditions

Symptomatic Neurogenic Orthostatic Hypotension; MSA; Parkinson's Disease (PD); Pure Autonomic Failure (PAF)

Interventions

ampreloxetine; Placebo

Participants

203

Sites

82

Countries

Australia, Austria, Bulgaria, Canada, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, New Zealand and more

Trials that died the same way

• TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
  “Stopped early due to company decision. Company decision based on interim analysis results in TD-1473-0157.” (89% match in meaning)
• Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
  “This study was terminated early due to company decision.” (62% match in meaning)
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
  “Company Decision” (61% match in meaning)
• PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
  “The study was terminated early due to company decision.” (61% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.